Journal of Antimicrobial Chemotherapy (1999) 44, 23-29
© 1999 The British Society for Antimicrobial Chemotherapy
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis
a Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, USA b Glaxo Wellcome Research and Development, Greenford, Middlesex, UK
Zanamivir, a potent, highly selective inhibitor of influenza virus A and B neuraminidase, has been evaluated in seven, similarly designed, placebo-controlled studies of the treatment of influenza. Patients with typical influenza symptoms were recruited when influenza was known to be circulating in the community. Six of these studies included a zanamivir 10 mg inhaled bd (for 5 days) treatment arm, the dose regimen submitted to regulatory agencies. Pooled analyses were conducted to evaluate efficacy more precisely in terms of the alleviation of symptoms in population subgroups and for secondary endpoints. Median time to alleviation of symptoms, the primary endpoint, was reduced from 6.0 days in the placebo group (n = 1102) to 5.0 days in the zanamivir group (n = 1133), P < 0.001. In febrile, laboratory-confirmed, influenza-positive (IP) patients, time to alleviation was reduced from 6.5 days to 5.0 days, a treatment benefit of 1.5 days (P < 0.001). A larger treatment benefit (3 days) was seen in IP patients who had severe symptoms at entry (n = 474, P < 0.001), compared with 1 day in patients whose symptoms were not severe (n = 1098, P < 0.001). Similarly, a 3 day treatment benefit (P = 0.003) was observed in IP patients aged <50 years (n = 263), compared with 1 day (P < 0.001) in patients aged <50 years. In ‘high-risk’ IP patients (recruited into all treatment studies), there was a treatment benefit of 2.5 days (n = 305, P = 0.006). Pooled analyses of secondary endpoints showed statistically significant reductions in antibiotic use, time to return to normal activities and use of relief medication. In addition, reductions in symptom scores were apparent shortly after commencing zanamivir treatment. By the evening of the second day of treatment, the median total symptom score had fallen by 44% in zanamivir recipients compared with 33% in placebo recipients (P < 0.001). These results highlight the groups likely to show greatest benefit from zanamivir treatment, and confirm the clinical relevance of the treatment benefit.
* Corresponding author. Tel: +1-734-764-5453; Fax: +1-734-764-3192; E-mail: asmonto{at}umich.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W S Lim Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic Thorax, January 1, 2007; 62(suppl_1): 1 - 46. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rothberg, S. Bellantonio, and D. N. Rose Management of Influenza in Adults Older than 65 Years of Age: Cost-Effectiveness of Rapid Testing and Antiviral Therapy Ann Intern Med, September 2, 2003; 139(5_Part_1): 321 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Bucher, P. Tschudi, J. Young, P. Periat, A. Welge-Lussen, H. Zust, and C. Schindler Effect of Amoxicillin-Clavulanate in Clinically Diagnosed Acute Rhinosinusitis: A Placebo-Controlled, Double-blind, Randomized Trial in General Practice Arch Intern Med, August 11, 2003; 163(15): 1793 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J Cooper, A. J Sutton, K. R Abrams, A. Wailoo, D. Turner, and K. G Nicholson Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials BMJ, June 5, 2003; 326(7401): 1235 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Oetke, R. Brossmer, L. R. Mantey, S. Hinderlich, R. Isecke, W. Reutter, O. T. Keppler, and M. Pawlita Versatile Biosynthetic Engineering of Sialic Acid in Living Cells Using Synthetic Sialic Acid Analogues J. Biol. Chem., February 15, 2002; 277(8): 6688 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Stephenson and K.G. Nicholson Influenza: vaccination and treatment Eur. Respir. J., June 1, 2001; 17(6): 1282 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Coonrod Influenza : Will New Diagnostic Tests and Antiviral Drugs Make a Difference? Chest, June 1, 2001; 119(6): 1630 - 1632. [Full Text] [PDF]
|
|
|
|
|
|
E. Hak, K. G. M. Moons, T. J. M. Verheij, A. W. Hoes, A. S. Monto, S. Gravenstein, M. Elliott, M. Colopy, and J. Schweinle Clinical Signs and Symptoms Predicting Influenza Infection Arch Intern Med, May 28, 2001; 161(10): 1351 - 1352. [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Sidwell, D. F. Smee, J. H. Huffman, D. L. Barnard, K. W. Bailey, J. D. Morrey, and Y. S. Babu In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201 Antimicrob. Agents Chemother., March 1, 2001; 45(3): 749 - 757. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. B. Couch Prevention and Treatment of Influenza N. Engl. J. Med., December 14, 2000; 343(24): 1778 - 1787. [Full Text] [PDF]
|
|